JANX · Janux Therapeutics, Inc.
$15.00
-0.57 (-3.66%)
At close · Jul 28
Market Cap
$914.77M
Shares
60.98M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.00
Open$15.57
Day$14.57–15.71
52W$12.12–35.34
Avg vol 30d1.3M
Short int6.5M · 10.6% float · 6.4d
Short vol51%
Last earningsDec 1, 2025
DataJun 2021–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−12%
below
Price vs 50-day avg
+1%
above
RSI (14)
45
neutral
MACD trend
Negative
52-week position
12%
near low
Momentum
relative strength
1-month return
0%
trailing
6-month return
+7%
trailing
YTD return
+9%
this year
Relative strength
0%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $15 › 200d $17 — 200d above 50d
Institutional flow
Accumulating
28 of 191 funds reported for Jun 30 · net +59.0K sh shares · +6 new
Insider flow
Distributing
Net -$85.8K over 90 days · 100% sells
Short interest
Falling
10.58% of float · ▼ -9.2% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
191 holders — mid 3-yr range
Squeeze score
74
high risk · 0–100
Fundamentals
Revenue growth
−6%
Y/Y
EPS growth
−43%
Y/Y
Free cash flow
$-83.3M
Balance sheet
$52.3M
net cash
Quant / Vol
risk profile
Volatility
75%
annualized · 1-yr
Max drawdown
−65%
past year
ATR
4.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−12%
Bearish
Price vs 50-day avg
+1%
Bullish
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
12%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $15 › 200d $17 — 200d above 50d
Institutional flow
Accumulating
28 of 191 funds reported for Jun 30 · net +59.0K sh shares · +6 new
Insider flow
Distributing
Net -$85.8K over 90 days · 100% sells
Short interest
Falling
10.58% of float · ▼ -9.2% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
191 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $12
Now $15 · 12%
52-wk high $35
vs 200-day avg -12%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JANX
this stock
Janux Therapeutics, Inc.
|
$914.77M | +8.7% | -6.1% | — | 10.6% |
|
ONC
BeOne Medicines Ltd.
|
$477.60B | +7.3% | +22179.2% | 971.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JANX | -6.5% | +0.4% | +7.2% | -2.3% | +8.7% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -5.6% | +0.4% | -0.2% | -1.6% | +0.1% |
Key facts
CIK
1817713
CUSIP
47103J105
13F (30d)
26 filings
26 filers
Visit website
Investor relations